bluebird bio Inc.

28.28-1.44-4.85%Vol 2.44M1Y Perf -46.19%
Apr 16th, 2021 16:00 DELAYED
BID28.01 ASK28.36
Open29.32 Previous Close29.72
Pre-Market- After-Market28.19
 - -  -0.09 -0.32%
Target Price
50.17 
Analyst Rating
Strong Buy 1.50
Potential %
77.40 
Finscreener Ranking
★★★★+     58.30
Insiders Trans % 3/6/12 mo.
-100/-100/-100 
Value Ranking
★★★★     56.75
Insiders Value % 3/6/12 mo.
-100/-100/-100 
Growth Ranking
★★★★+     64.14
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-100 
Income Ranking
 —    -
Market Cap1.90B 
Earnings Rating
Buy
Price Range Ratio 52W %
8.37 
Earnings Date
10th May 2021

Today's Price Range

27.9929.84

52W Range

24.2472.50

5 Year PE Ratio Range

-11.30-6.90

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
0.43%
1 Month
-8.77%
3 Months
-44.03%
6 Months
-49.59%
1 Year
-46.19%
3 Years
-83.47%
5 Years
-43.87%
10 Years
-

TickerPriceChg.Chg.%
BLUE28.28-1.4400-4.85
AAPL134.16-0.3400-0.25
GOOG2 297.761.10000.05
MSFT260.741.24000.48
XOM56.66-0.3200-0.56
WFC43.841.60003.79
JNJ162.241.85001.15
FB306.18-1.6400-0.53
GE13.39-0.1600-1.18
JPM153.301.13000.74
Financial StrengthValueIndustryS&P 500US Markets
5.80
6.00
0.11
0.14
-
Leverage Ratio 1.30
ProfitabilityValueIndustryS&P 500US Markets
97.90
-261.50
-253.70
-1 654.20
-
RevenueValueIndustryS&P 500US Markets
228.87M
3.41
64.59
92.30
Earnings HistoryEstimateReportedSurprise %
Q04 2020-3.02-3.010.33
Q03 2020-3.07-2.944.23
Q02 2020-1.91-0.3681.15
Q01 2020-3.94-3.647.61
Q04 2019-3.81-4.04-6.04
Q03 2019-3.53-3.73-5.67
Q02 2019-3.03-3.55-17.16
Q01 2019-2.80-2.99-6.79
Earnings Per EndEstimateRevision %Trend
3/2021 QR-3.050.65Positive
6/2021 QR-2.98-0.34Negative
12/2021 FY-11.73-0.51Negative
12/2022 FY-9.90-2.91Negative
Next Report Date10th May 2021
Estimated EPS Next Report-3.02
Estimates Count12
EPS Growth Next 5 Years %-
Volume Overview
Volume2.44M
Shares Outstanding67.14M
Trades Count15.07K
Dollar Volume226.42M
Avg. Volume2.20M
Avg. Weekly Volume1.30M
Avg. Monthly Volume1.78M
Avg. Quarterly Volume2.36M

bluebird bio Inc. (NASDAQ: BLUE) stock closed at 28.28 per share at the end of the most recent trading day (a -4.85% change compared to the prior day closing price) with a volume of 2.45M shares and market capitalization of 1.90B. Is a component of Russell 1000 indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 1213 people. bluebird bio Inc. CEO is Nick Leschly.

The one-year performance of bluebird bio Inc. stock is -46.19%, while year-to-date (YTD) performance is -34.64%. BLUE stock has a five-year performance of -43.87%. Its 52-week range is between 24.24 and 72.5, which gives BLUE stock a 52-week price range ratio of 8.37%

bluebird bio Inc. currently has a PE ratio of -2.90, a price-to-book (PB) ratio of 1.43, a price-to-sale (PS) ratio of 8.21, a price to cashflow ratio of 5.70, a PEG ratio of 2.32, a ROA of -33.79%, a ROC of -38.67% and a ROE of -44.93%. The company’s profit margin is -%, its EBITDA margin is -253.70%, and its revenue ttm is $228.87 Million , which makes it $3.41 revenue per share.

Of the last four earnings reports from bluebird bio Inc., there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $-3.02 for the next earnings report. bluebird bio Inc.’s next earnings report date is 10th May 2021.

The consensus rating of Wall Street analysts for bluebird bio Inc. is Strong Buy (1.5), with a target price of $50.17, which is +77.40% compared to the current price. The earnings rating for bluebird bio Inc. stock is Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

bluebird bio Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

bluebird bio Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 22.59, ATR14 : 2.26, CCI20 : -72.44, Chaikin Money Flow : -0.25, MACD : -2.88, Money Flow Index : 54.43, ROC : -1.19, RSI : 40.47, STOCH (14,3) : 17.94, STOCH RSI : 0.68, UO : 46.52, Williams %R : -82.06), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of bluebird bio Inc. in the last 12-months were: Alison Cecily Finger (Sold 2 102 shares of value $97 569 ), Andrew Obenshain (Sold 817 shares of value $23 660 ), David Davidson (Sold 4 376 shares of value $188 533 ), Douglas G. Cole (Sold 3 706 shares of value $163 401 ), Katy Burnett (Sold 641 shares of value $20 256 ), Kory J. Wentworth (Sold 832 shares of value $54 610 ), Nick Leschly (Sold 14 566 shares of value $685 783 ), Philip D. Gregory (Sold 3 974 shares of value $172 055 ), William D. Baird (Sold 2 858 shares of value $117 624 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
13 (72.22 %)
13 (72.22 %)
12 (70.59 %)
Moderate Buy
1 (5.56 %)
1 (5.56 %)
0 (0.00 %)
Hold
4 (22.22 %)
4 (22.22 %)
5 (29.41 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.50
Strong Buy
1.50
Moderate Buy
1.59

bluebird bio Inc.

bluebird bio Inc is a clinical-stage biotechnology company that develops gene therapies for severe genetic and rare diseases. The company's gene therapy procedures aim to genetically modify a patient's cells to fundamentally correct or address the genetic basis underlying a disease. Bluebird's revenue is derived from collaboration arrangements, research fees, license fees, and grant revenue. The company works with industry peers, strategic partners, and nonprofit organizations for the development and commercialization of its product candidates.

CEO: Nick Leschly

Telephone: +1 339 499-9300

Address: 60 Binney Street, Cambridge 02142, MA, US

Number of employees: 1 213

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

100%0%

Bearish Bullish

69%31%

Bearish Bullish

51%49%

Bearish Bullish

60%40%

News

Stocktwits